The FDA alerts of people overdosing on compounded semaglutide weight-loss drugs, causing hospitalizations due to incorrect dosages of 5 to 20 times higher than intended.
Compounded semaglutide lacks FDA safety approval, posing higher risks, including confusion from unapproved sourcing by pharmacies. FDA-approved semaglutide for obesity management has driven its popularity despite affordability issues.
Collection
[
|
...
]